[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ad-mci\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ad-mci":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,77],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100642440","temporal-interference-stimulation-treatment-in-patients-with-cognitive-impairment-100642440",false,"NCT07643363","Temporal Interference Stimulation Treatment in Patients With Cognitive Impairment","A Randomized, Sham-Controlled Trial of Temporal Interference Stimulation Treatment in Patients With Cognitive Impairment","TIS","Inclusion Criteria:\n\n* meets the criteria for probable AD and MCI due to AD as defined by the 2024 National Institute on Aging-Alzheimer's Association (NIA-AA) guidelines;\n* Positive amyloid biomarker (amyloid PET or CSF tTau\u002FAβ 42);\n* Positive tau biomarker (tau-PET or CSF pTau181);\n* AD-related standard treatments (acetyl cholinesterase inhibitors and N-methyl-D-aspartate receptor antagonists) taken at a stable dose for at least 12 weeks prior to baseline.\n* meets the criteria for probable bvFTD as defined by the revised diagnostic criteria for the behavioural variant of frontotemporal dementia (2011), or PPA as defined by the Classification of primary progressive aphasia and its variants (2011);\n* Optional genetic confirmation of FTD-related pathogenic mutations (if available).\n* Aged between 45 and 85 years, inclusive; no gender limitation.\n* Right-handed.\n* Education level ≥ 3 years.\n* Mini-Mental State Examination (MMSE) score ≥ 11.\n* Clinical Dementia Rating (CDR) score of 1 or 2.\n* with a reliable caregiver\n* Able to cooperate with cognitive assessments and cognitive training procedures.\n* Full understanding of the study, voluntary participation, and provision of written informed consent approved by the Ethics Committee.\n\nExclusion Criteria:\n\n* Diagnosis of other types of dementia or major neurological disorders (e.g., stroke, epilepsy, Lewy body dementia, vascular dementia, Parkinson's disease dementia, Huntington's disease).\n* Major psychiatric disorders such as severe depression or anxiety.\n* Severe systemic or organ dysfunction (e.g., heart failure III-IV, liver cirrhosis, renal failure).\n* Use of medications that significantly affect cognition (e.g., anticholinergics, sedatives), unless approved by the physician.\n* Presence of metal implants incompatible with MRI or TIS (e.g., pacemakers, deep brain stimulators).\n* Skull defects or cranial abnormalities.\n* Inability to tolerate EEG or head stabilization.\n* Severe visual or hearing impairment preventing task performance.\n* History of alcohol or drug abuse.\n* Participation in another clinical trial within the past 3 months.\n* Current or recent treatment with anti-amyloid monoclonal antibodies (e.g., lecanemab, donanemab).","ALL","45 Years","85 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study aims to evaluate the efficacy and safety of temporal interference stimulation (TIS), a non-invasive neuromodulation technique, in improving cognitive function in patients with cognitive impairment. TIS uses two high-frequency currents applied transcranially, which intersect within the brain to generate a low-frequency modulation field. This technique selectively modulates deep brain regions while minimizing the stimulation of superficial cortical layers.\n\nParticipants will undergo individualized MRI-based modeling to determine the optimal electrode placement and stimulation parameters. The intervention consists of 10 stimulation sessions over a period of 14 days, using either active TIS or sham stimulation. Cognitive assessments, EEG recordings, and functional MRI scans will be conducted at baseline; 5 days after intervention initiation; at the end of the 10-day intervention; and during follow-up assessments at 4 weeks, 8 weeks, and 12 weeks post-intervention to evaluate both immediate and long-term effects on cognitive performance and neural activity.\n\nThe study aims to determine whether TIS can serve as a feasible and effective neuromodulation strategy for individuals with cognitive impairment.",[28,29,30,31],"Amnestic Mild Cognitive Impairment - aMCI","AD-MCI","AD - Alzheimer's Disease","FTD",[33,34,35],"Temporal Interference Stimulation","Alzheimer's Disease","Frontotemporal Dementia","RECRUITING","2026-06-08",{"date":39,"type":40},"2026-06-11","ACTUAL",{"date":42,"type":22},"2026-07-01",{"date":44,"type":22},"2029-06",{"name":46,"class":47},"Tianjin Huanhu Hospital","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":48},"100632336","phase-2-human-mesenchymal-stem-cells--monoclonal-antibodies-in-the-treatment-for-mild-cognitive-impairment-or-early-alzheimers-disease-100632336","NCT07512362","Human Mesenchymal Stem Cells & Monoclonal Antibodies in the Treatment for Mild Cognitive Impairment or Early Alzheimer's Disease.","A Pilot Study to Assess the Effect of Adding 1 Infusion of Human Mesenchymal Stem Cells (hMSC) to Patients Treated With Anti-Amyloid Monoclonal Antibodies Who Are Suffering From Mild Cognitive Impairment or Mild Alzheimer's Disease.","Inclusion Criteria:\n\n* Adults 55-90 years at the time of signing consent\n* Patients diagnosed with Mild Cognitive Impairment or mild Dementia due to Alzheimer disease, receiving treatment with an FDA approved monoclonal antibody (Leqembi\u002FLecanemab or Kisunla\u002FDonanemab) for at least 6 months prior to the infusion visit.\n* MMSE score 20-26.\n* Patients must be able to consent.\n* Have a family member or friend (study partner) who has frequent and sufficient contact with the patient and is able to answer questions about the participant's daily activities to complete the ADCS-MCI-ADL. Completing this scale is required to assess the impact of the study intervention on cognitive function and daily living skills in this patient population. Having a study partner is a requirement of this study.\n\nExclusion Criteria:\n\n* Dementia other than AD\n* Patient with severe depression. Patients with controlled depression are allowed to participate.\n* Inability to independently provide informed consent is considered exclusionary per protocol requirements\n* Recent history of substance abuse\n* History of bleeding disorders, HIV, HCV or HBV\n* Recent history (within 3 years) of malignancies, except for treated basal cell, squamous carcinoma or melanoma in situ, prostate in situ, cervical carcinoma in situ.\n* Uncontrolled medical conditions (hypertension, diabetes, unstable angina or MI within 1 year prior to screening)\n* History of bleeding disorder\n* Currently receiving (or received within four weeks of screening) experimental agents for the treatment of Alzheimer's Disease or enrolled in clinical trials in the prior 3 months.\n* Be a transplant recipient or in any other active medical condition than in the opinion of the investigator may compromise the safety or compliance of the patient or preclude successful completion of the study\n* Be premenopausal","55 Years","90 Years",{"count":59,"type":22},10,[61],"PHASE2","The purpose of this study is to test if adding one infusion of (Human Mesenchymal Stem Cells) hMSCs to the treatment with standard of care (SOC) monoclonal antibodies (mAb) will stabilize the rate of cognitive and functional decline associated with mild Alzheimer's Disease.",[64,65,29],"Mild Cognitive Impairment","Early Alzheimer's Disease",[64,67,29,65],"MCI","2026-05-26",{"date":70,"type":40},"2026-05-28",{"date":72,"type":40},"2026-05-15",{"date":74,"type":22},"2028-06-15",{"name":76,"class":47},"Bernard (Barry) Baumel",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":84,"maxAge":19,"enrollmentInfo":85,"targetDuration":4,"studyType":23,"phases":87,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":48},"100552206","clinical-multicenter-randomized-controlled-study-of-non-invasive-brain-oscillation-modulation-in-the-treatment-of-ad-mci-patients-100552206","NCT06470074","Clinical Multicenter Randomized Controlled Study of Non-invasive Brain Oscillation Modulation in the Treatment of AD-MCI Patients","Xuanwu Hospital, Capital Medical University","Inclusion Criteria:\n\nMale or female AD-MCI patients between the ages of 50-85; The psychological evaluation was in accordance with MMSE score of 18-30 (including 18 and 30) and CDR score of 0.5.\n\nCan cooperate to complete clinical research.\n\nExclusion Criteria:\n\nThere is a definite history of cerebrovascular stroke, and there are definite symptoms or signs of neurological deficit at the time of onset, and there are corresponding responsible lesions left by neuroimaging.\n\nThose who have a history of alcoholism, or drug addiction, or neurological diseases such as brain trauma, epilepsy, encephalitis, normal intracranial pressure hydrocephalus, etc. that can cause cognitive impairment.\n\nSuffering from systemic diseases that may lead to cognitive impairment (such as liver and kidney insufficiency, endocrine diseases, vitamin deficiency).\n\nHave a history of using antipsychotics for more than five years before diagnosis.\n\nThere are contraindications for head MRI examination.","50 Years",{"count":86,"type":22},124,[25],"A multicenter randomized controlled clinical study was conducted in the Xuanwu hospital of Capital Medical University to preliminarily explore the efficacy and safety of transcranial electrical stimulation in the treatment of AD-MCI patients, to clarify the effective mechanism and form an effective clinical treatment plan.",[29],"NOT_YET_RECRUITING","2024-06-17",{"date":93,"type":40},"2024-06-24",{"date":95,"type":22},"2024-09",{"date":97,"type":22},"2026-11",{"name":99,"class":47},"Xuanwu Hospital, Beijing"]